Ignaut Debra A, Schwartz Sherwyn L, Sarwat Samiha, Murphy Heather L
Insulin/Devices Medical, Eli Lilly and Company, Indianapolis, Indiana (Dr Ignaut, Ms Sarwat, Ms Murphy)
The Diabetes/Glandular Disease Clinic, San Antonio, Texas (Ms Schwartz)
Diabetes Educ. 2009 Sep-Oct;35(5):789-98. doi: 10.1177/0145721709340056.
The purpose of this study was to compare pen device-naïve patients' preferences for Humalog KwikPen (insulin lispro injection) (Eli Lilly and Company, Indianapolis, IN) to use of a vial and syringe and FlexPen(R) (insulin aspart injection) (Novo Nordisk A/S, Bagsvaerd, Denmark).
This open-label, randomized, crossover 1-day study tested the hypotheses that KwikPen was preferred to vial and syringe, and if this was found to be a significant preference, that KwikPen was preferred to FlexPen. Accuracy of doses prepared, ease of use via insulin device assessment battery, and preference via insulin device preference battery were administered following each pen evaluation, and a final preference question administered following the evaluation of both pens. Clinical measures were not included as subjects injected into an appliance to simulate the injection experience. Primary outcome variables were evaluated by Question 13 of the insulin device preference battery and the final preference question.
Among 232 enrolled patients randomized to 1 of 4 sequences (n = 58), Humalog KwikPen was significantly preferred over vial and syringe and over FlexPen. After patients were asked to assess Humalog KwikPen or FlexPen versus V&S by choosing "strongly agreed" or "agreed" to the following attributes: easy to use, easy to hold in their hands when injecting, and easy to press the injection button, the results exhibited significant differences in patient responses. Humalog KwikPen was significantly more accurate and was preferred to vial and syringe in appearance, quality, discretion, convenience, public use, easy to learn, easy to use, reliability, dose confidence, following insulin regimen, overall satisfaction, and recommendation to others.
Humalog KwikPen was significantly preferred over vial and syringe and FlexPen. When compared with vial and syringe, Humalog KwikPen and FlexPen were easier to use and operate, demonstrated superior accuracy of doses prepared, and preferred by pen-naïve users.
本研究旨在比较初次使用笔式装置的患者对优泌乐笔(赖脯胰岛素注射液)(礼来公司,印第安纳波利斯,印第安纳州)与使用小瓶和注射器以及诺和锐笔(门冬胰岛素注射液)(诺和诺德公司,丹麦 Bagsvaerd)的偏好。
这项开放标签、随机、交叉的 1 天研究检验了以下假设:笔式胰岛素注射装置比小瓶和注射器更受青睐,如果发现这种偏好具有显著性,那么笔式胰岛素注射装置比诺和锐笔更受青睐。在每次笔式装置评估后,通过胰岛素装置评估量表评估所准备剂量的准确性、使用便捷性,并通过胰岛素装置偏好量表评估偏好情况,在两种笔式装置评估后提出一个最终偏好问题。由于受试者向一个模拟注射体验的器具中注射,因此未纳入临床测量指标。主要结局变量通过胰岛素装置偏好量表的问题 13 和最终偏好问题进行评估。
在 随机分为 4 种序列之一(n = 58)的 232 名入组患者中,优泌乐笔比小瓶和注射器以及诺和锐笔更受显著青睐。在患者被要求通过对以下属性选择“强烈同意”或“同意”来评估优泌乐笔或诺和锐笔相对于小瓶和注射器的情况:易于使用、注射时易于手持、易于按下注射按钮后,患者的回答显示出显著差异。优泌乐笔显著更准确,在外观、质量便利性、公开使用、易于学习、易于使用、可靠性、剂量可信度、遵循胰岛素治疗方案、总体满意度以及向他人推荐等方面比小瓶和注射器更受青睐。
优泌乐笔比小瓶和注射器以及诺和锐笔更受显著青睐。与小瓶和注射器相比,优泌乐笔和诺和锐笔更易于使用和操作,所准备剂量的准确性更高,且更受初次使用笔式装置的用户青睐。